Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ATM | Q13315 | 1/20 | 0.58 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.58 |
| ▸ | MAPT | P10636 | 3/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | BACE1 | P56817 | 1/20 | 0.41 |
| ▸ | HSPB1 | P04792 | 3/20 | 0.41 |
| ▸ | PDE7A | Q13946 | 1/20 | 0.40 |
| ▸ | TTR | P02766 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.39 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.39 |
| ▸ | FBP1 | P09467 | 1/20 | 0.39 |
| ▸ | KCNMA1 | Q12791 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.38 |
| ▸ | CASP6 | P55212 | 1/20 | 0.38 |
| ▸ | SNCA | P37840 | 1/20 | 0.38 |
| ▸ | PKM | P14618 | 1/20 | 0.37 |
| ▸ | EGFR | P00533 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14833771 | 0.85 | TDP1 (0.53) | ATMTDP1MAPTLMNAHSPB1 | |
| SCHEMBL29547124 | 0.83 | ATM (0.60) | ATMTDP1MAPTLMNABACE1 | |
| SCHEMBL564611 | 0.83 | ATM (0.60) | ATMTDP1MAPTLMNABACE1 | |
| SCHEMBL16951913 | 0.81 | ATM (0.58) | ATMTDP1MAPTLMNABACE1 | |
| SCHEMBL24137366 | 0.81 | ATM (0.58) | ATMTDP1MAPTLMNABACE1 | |
| SCHEMBL3512661 | 0.79 | ATM (0.55) | ATMTDP1MAPTLMNABACE1 | |
| SCHEMBL3512659 | 0.79 | ATM (0.55) | ATMTDP1MAPTLMNABACE1 | |
| SCHEMBL16951426 | 0.78 | ERN1 (0.45) | ATMTDP1MAPTLMNABACE1 | |
| SCHEMBL6562672 | 0.78 | BACE1 (0.61) | MAPTBACE1ALDH1A1L3MBTL1EGFR | |
| SCHEMBL14468256 | 0.78 | BACE1 (0.38) | ATMTDP1MAPTBACE1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12110293-B2 | Substituted triazolo quinoxaline derivatives | Grünenthal GmbH (DE) | 2024-10-08 | — | — | US | disclosed |
| CN-112673009-B | Substituted triazoloquinoxaline derivatives | 格吕伦塔尔有限公司 | 2023-09-19 | — | — | CN | disclosed |
| EP-3823971-B1 | SUBSTITUTED TRIAZOLO QUINOXALINE DERIVATIVES | GRUENENTHAL GMBH (DE) | 2022-07-27 | — | — | EP | disclosed |
| EP-3823971-A1 | SUBSTITUTED TRIAZOLO QUINOXALINE DERIVATIVES | Grünenthal GmbH (DE) | 2021-05-26 | — | — | EP | disclosed |
| US-20210139488-A1 | SUBSTITUTED TRIAZOLO QUINOXALINE DERIVATIVES | Grünethal GmbH (DE) | 2021-05-13 | — | — | US | disclosed |
| CN-112673009-A | Substituted triazoloquinoxaline derivatives | 格吕伦塔尔有限公司 | 2021-04-16 | — | — | CN | disclosed |
| WO-2020016453-A1 | SUBSTITUTED TRIAZOLO QUINOXALINE DERIVATIVES | Grünenthal GmbH (DE) | 2020-01-23 | — | — | WO | disclosed |
| EP-2900645-A1 | 3-PHENYLISOXAZOLIN DERIVATIVES WITH HERBICIDAL ACTION | Bayer CropScience AG (DE) | 2015-08-05 | — | — | EP | disclosed |
| US-8557805-B2 | Fused ring compound and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2013-10-15 | — | — | US | disclosed |
| US-20120035163-A1 | NOVEL FUSED RING COMPOUND AND USE THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED | 2012-02-09 | — | — | US | disclosed |
| EP-2005177-A1 | A HOMOGENEOUS TIME RESOLVED FLUORESCENCE BASED TEST SYSTEM | Tibotec Pharmaceuticals Ltd. (IE) | 2008-12-24 | — | — | EP | disclosed |
| EP-1667989-A4 | SUBSTITUTED ISOQUINOLINONES | PORTOLA PHARM INC (US) | 2008-08-20 | — | — | EP | disclosed |
| US-7294635-B2 | Substituted isoquinolinones | PORTOLA PHARMACEUTICALS, INC. (US) | 2007-11-13 | — | — | US | disclosed |
| US-7294635-B2 | Substituted isoquinolinones | PORTOLA PHARMACEUTICALS, INC. (US) | 2007-11-13 | — | — | US | disclosed |
| US-7294635-B2 | Substituted isoquinolinones | PORTOLA PHARMACEUTICALS, INC. (US) | 2007-11-13 | — | — | US | disclosed |
| WO-2007113337-A1 | A HOMOGENEOUS TIME RESOLVED FLUORESCENCE BASED TEST SYSTEM | TIBOTEC PHARMACEUTICALS LTD. (IE) | 2007-10-11 | — | — | WO | disclosed |
| WO-2007113337-A1 | A HOMOGENEOUS TIME RESOLVED FLUORESCENCE BASED TEST SYSTEM | TIBOTEC PHARMACEUTICALS LTD. (IE) | 2007-10-11 | — | — | WO | disclosed |
| EP-1667989-A1 | SUBSTITUTED ISOQUINOLINONES | Portola Pharmaceuticals, Inc. (US) | 2006-06-14 | — | — | EP | disclosed |
| US-20050113399-A1 | Substituted isoquinolinones | PORTOLA PHARMACEUTICALS, INC. (US) | 2005-05-26 | — | — | US | disclosed |
| WO-2005035520-A1 | SUBSTITUTED ISOQUINOLINONES | PORTOLA PHARMACEUTICALS, INC. (US) | 2005-04-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050113399-A1 | Substituted isoquinolinones | PFKP, MPL, TBXA2R | ATM 499/4885TDP1 226/4885MAPT 4564/4885 |
| US-20210139488-A1 | SUBSTITUTED TRIAZOLO QUINOXALINE DERIVATIVES | NR3C1, NR3C2, GRK5 | ATM 2721/4885TDP1 3322/4885MAPT 4676/4885 |
| US-20120035163-A1 | NOVEL FUSED RING COMPOUND AND USE THEREOF | GPR119, GCKR, SLC5A1 | ATM 2440/4885TDP1 3718/4885MAPT 4051/4885 |
| US-12110293-B2 | Substituted triazolo quinoxaline derivatives | NR3C1, NR3C2, GRK5 | ATM 2721/4885TDP1 3322/4885MAPT 4676/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.